Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

It features thorough molecular simulations of the receptor within its native membrane environment, complemented by ensemble virtual screening that considers its conformational mobility. For dimeric or oligomeric receptors, the full functional complex is constructed, and tentative binding sites are determined on and between the subunits to cover the entire spectrum of potential mechanisms of action.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q99062

UPID:
CSF3R_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q99062

BACKGROUND:
The protein known as Granulocyte colony-stimulating factor receptor, with the recommended name and accession Q99062, is crucial for granulocytic maturation. It acts as a receptor for CSF3, essential for the proliferation, differentiation, and survival of neutrophilic lineage cells. Additionally, it may have roles in cell surface adhesion or recognition.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Granulocyte colony-stimulating factor receptor could open doors to potential therapeutic strategies for addressing hereditary neutrophilia and severe congenital neutropenia 7, autosomal recessive. These diseases, linked to mutations affecting the receptor's gene, underscore the importance of G-CSFR in maintaining neutrophil homeostasis and immune defense.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.